Clinical trials in Capelle Aan Den Ijssel – page 9

1 543 clinical trials in Capelle Aan Den Ijssel, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Capelle Aan Den Ijssel at a glance

1 543

clinical trials

Research sites1

Quick filters

1 543 trials in Capelle Aan Den Ijssel

Open in trial search

Hepatic cirrhosis

Recruiting

Low‑dose human serum albumin versus standard dose during large‑volume paracentesis in patients with liver cirrhosis

Registered drugNo placebo

Low‑dose human serum albumin versus standard dose during large‑volume paracentesis in patients with liver cirrhosis

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Human Serum Albumin
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Amyotrophic lateral sclerosis

Recruiting

Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Investigational

Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:TRCN-1023
Sponsor:Trace Neuroscience Inc.

Contact Research Centre

Duchenne muscular dystrophy+1

Recruiting

Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

InvestigationalNo placebo

Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:ENTR-601-44
Sponsor:Entrada Therapeutics Inc.

Contact Research Centre

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:AZD0901
Sponsor:AstraZeneca AB

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Azacitidine
Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Contact Research Centre

Rheumatoid arthritis

Recruiting

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Sint Maartenskliniek

Contact Research Centre

Chronic lymphocytic leukaemia+2

Recruiting

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Venetoclax
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Alpha-1 antitrypsin deficiency

Recruiting

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:RNACS24757
Sponsor:Tessera Therapeutics Inc.

Contact Research Centre

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:GIA632
Sponsor:Novartis Pharma AG

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Capelle Aan Den Ijssel

What the registry says about research in the country

01 Oncology - Colorectal Studies

Multiple innovative trials focusing on colorectal cancer treatment strategies, including research on liver metastases management and chemotherapy optimization for older patients.

Hepatic arterial infusion therapy
Dose-adjusted chemotherapy protocols
Post-surgical treatment approaches

Advanced research exploring both surgical and medical interventions for improved patient outcomes.

02 Hematology & Breast Cancer

Groundbreaking studies in multiple myeloma treatment protocols and innovative approaches for hormone receptor-positive breast cancer management.

Treatment-free interval assessment
CDK 4/6 inhibition strategies
Endocrine therapy optimization

Focus on developing personalized treatment strategies for better long-term outcomes.

03 Inflammatory & Autoimmune Conditions

Comprehensive research on rheumatoid arthritis management, investigating novel treatment timing and personalized therapeutic approaches.

Chronotherapy effectiveness
Tailored management protocols
Cost-effectiveness analysis

Emphasis on patient-centered outcomes and treatment optimization.

Back to the Netherlands All countries